Navigation Links
BioTrends Research Group is Recognized by the Philly 100 for the Second Consecutive Year
Date:9/8/2009

EXTON, Pa., Sept. 8 /PRNewswire/ -- For the second year in a row, BioTrends Research Group, Inc. has been ranked as one of the fastest-growing, privately-held companies in the Philadelphia region by the Philadelphia 100, a joint project of the Wharton Small Business Development Center, the Entrepreneurs' Forum of Greater Philadelphia, and the Philadelphia Business Journal.

Over the past five years, BioTrends has become an established player in the field of syndicated market research in the healthcare sector. "In spite of industry cut-backs, our business has flourished in the past two years. We believe this is due to our unique offering - high quality primary market research conducted in specialty pharmaceutical markets and shared across multiple clients which, in turn, provides a cost effective alternative to traditional single client proprietary projects," says Sharon Funk, Vice President of Market Research Services at BioTrends.

Originally focused entirely in Nephrology, BioTrends now offers syndicated reports in multiple specialties and therapeutic categories including Multiple Sclerosis, Rheumatoid Arthritis, Psoriasis, Gout/Hyperuricemia, Inflammatory Bowel Disease, and Lupus. The 2010 Publication Plan, published earlier this week, includes over 50 planned publications with new categories such as Fibromyalgia, Hepatitis, Macular Degeneration and Hypertension.

"We expect 2010 to be another exciting year for BioTrends as we expand into new therapeutic and new geographic areas. We are currently in the process of identifying savvy industry professionals to join the BioTrends team in 2010 to help us capitalize on the tremendous demand for our products and services" says Jennifer Robinson, Founder and President of BioTrends.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To learn more, please contact us at (610) 363-3872 or visit us at www.bio-trends.com

About the Philly 100

For more information on the Philadelphia 100, visit www.philadelphia100.com.

CONTACT: Jennifer Robinson of BioTrends Research Group, Inc., +1-610-363-3872, jrobinson@bio-trends.com


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists
2. Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market
3. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
4. European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report
5. BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
6. BioTrends Research Group, Inc. Recognized as One of Philadelphias Fastest Growing Privately Held Companies
7. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
8. BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
9. New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists
10. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
11. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... During a ... technology into a viable company, CereScan’s CEO, John Kelley, joined other Denver business ... leader and mentor in the Denver area business community, shared his top fundamental ...
(Date:4/28/2016)... India , April 28, 2016 ... JT, Stirling, and Brayton Cryocoolers), Service (Technical Support, Product ... and Geography - Global Forecast to 2022", published by ... USD 2.94 Billion by 2022, at a CAGR of ... 70 market data Tables and 94 Figures spread through ...
(Date:4/28/2016)... ... April 28, 2016 , ... As ... recruiting top industry experts, and expanding its LATAM network and logistics capabilities. ... clients to manage their clinical trial projects. , The expansion will provide unmatched ...
(Date:4/27/2016)... ... 2016 , ... The Pittcon Organizing Committee is pleased to announce that Charles ... member of Committee since 1987. Since then, he has served in a number of ... chairman for both the program and exposition committees. In his professional career, Dr. Gardner ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):